Adipotide FTPP Peptide

Overview

Adipotide FTPP is a proapoptotic research peptide that has been investigated for its potential to selectively target white adipose (fat) tissue. Preclinical research suggests it may reduce the blood supply to white fat cells while leaving surrounding tissues largely unaffected. Animal studies have explored its possible role in weight management, insulin sensitivity, glucose metabolism, and metabolic health.

Specifications

• Other Known Titles: Adipotide
• Molecular Formula: C152H252N44O42
• Molecular Weight: 2611.41 g/mol
• Sequence: Cys-Lys-Gly-Gly-Arg-Ala-Lys-Asp-Cys-Gly-Gly-(Lys-Leu-Ala-Lys-Leu-Ala-Lys)₂

Research Overview

Research suggests that Adipotide may bind to the ANXA2 (Annexin A2) and Prohibitin (PHB) receptor complex found within the blood vessels supplying white adipose tissue. This interaction has been investigated for its potential role in disrupting fatty acid transport, reducing blood supply to fat cells, and initiating programmed cell death (apoptosis).

Scientists have also explored the relationship between ANXA2, Prohibitin, and the fatty acid transporter CD36, proposing that this receptor system may influence fatty acid uptake and storage within white adipose tissue.

Structure & Mechanism

Adipotide contains the peptide sequence GKGGRAKDC-GG-D(KLAKLAK)₂. The targeting segment is believed to recognize Prohibitin receptors on adipose blood vessels, while the (KLAKLAK)₂ portion has been studied for its potential to disrupt mitochondrial membranes following cellular internalization, leading to apoptosis of targeted cells.

Potential Research Applications

Current laboratory investigations have explored Adipotide FTPP in the following research areas:

• White adipose tissue biology
• Fat metabolism studies
• Obesity research
• Glucose tolerance and insulin sensitivity
• Metabolic syndrome
• Type 2 diabetes research
• Vascular-targeted peptide therapies
• Cancer-related vascular targeting
• Fatty liver research

Fat Loss Research

Studies conducted in rhesus monkeys reported reductions in body weight, body mass index (BMI), and improvements in insulin sensitivity following Adipotide administration. Researchers also observed reductions in appetite during some studies, although it remains unclear whether this represents a direct biological effect or a secondary response to changes in adipose tissue.

Cancer & Metabolic Research

Because Prohibitin receptors have been identified in both adipose tissue and certain cancer cells, researchers continue to investigate Adipotide for its potential role in vascular-targeted cancer research. Additional studies have explored possible links between obesity, inflammatory pathways, insulin signaling, IGF-1 activity, and tumor progression.

Future Research

Ongoing investigations continue to evaluate Adipotide FTPP for its potential role in obesity, diabetes, metabolic disorders, adipose tissue biology, vascular targeting, and other experimental research applications. Additional laboratory studies are required to better understand its mechanisms and long-term scientific potential.